FDA 483 OBSERVATION · #225 OF 1,945 MOST-CITED

Identity Testing of Each Component

FDA cited this observation 132 times across 124 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs132
BY FISCAL YEAR
FY202621
FY202530
FY202423
FY202313
FY20228
FY20211
FY201910
FY20186
FY201711
FY20169

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 5.9× the rate of the average FDA-cited firm (46.0% vs 7.8%), across 124 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests if they exist.

Noven Pharmaceuticals, Inc. · Miami, Florida · Drugs · 2026-08-24

The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests if they exist.

AVEVA Drug Delivery Systems, Inc. · Miramar, Florida · Drugs · 2026-08-14

The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests if they exist.

Steril-Gene Life Sciences Private Ltd · Puducherry · Drugs · 2026-08-12

The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests if they exist.

Aizant Drug Research Solutions Private Ltd. · Hyderabad · Drugs · 2026-07-31

The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests if they exist.

Prime Enterprises LLC · Hialeah, Florida · Drugs · 2026-07-13

The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests if they exist.

Biokosmes Srl · Bosisio Parini · Drugs · 2026-06-26

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →